Project Grant R44CA221539

This Project Grant award of $1,396,152.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to examine the role of the protein BNIP3 and mitophagy (selective degradation of mitochondria) in muscle atrophy during cancer cachexia associated with pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse models of PDAC to investigate how BNIP3 promotes atrophy of muscle fibers by reducing mitochondrial mass, and how reconstitution...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $635,248 to Trustees of Boston University to develop a novel self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T cell engager (BITE) antibody for the treatment of lung cancer. The key goals are to: Design 5-methylcytidine (5MC) modified SARNA constructs encoding BITE antibodies and evaluate their protein expression performance in vitro. Assess the in vitro and in...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $639,004 to Mayo Clinic from January 1, 2025 to December 31, 2029 to conduct research on using a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The key products and services to be delivered under this award include: Collecting and processing pre- and post-treatment tumor tissue and peripheral blood samples...

This Project Grant award of $188,169.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The key objectives are to complete proof-of-concept studies evaluating the biological activity and efficacy of the AAV vector in killing cancer cells through in vitro assays and xenograft mouse models. The...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $432,889 to The Johns Hopkins University to conduct research aimed at advancing cancer screening, diagnostic technologies, and early detection methodologies. The project, titled "Molecular Imaging and Metabolotheranostics of PDAC-Induced Cachexia", will focus on reversing cachexia (severe muscle wasting) induced by pancreatic ductal adenocarcinoma...

The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc. on September 19, 2024. The goal of this STTR project is to develop an RNA interference-based therapeutic to treat prostate cancer. The therapeutic, termed "NU002", will use lipopolyplex nanoparticles to deliver short interfering RNAs (siRNAs) derived from CAG trinucleotide repeat sequences....

This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $130,501 to The Salk Institute for Biological Studies to conduct research on the role of muscle CDKN1A in cancer cachexia. The key objectives are to: 1) elucidate the function of muscle CDKN1A in muscle dysfunction during cancer cachexia, 2) define the temporal regulation of CDKN1A by BCL6 in response to nutrient availability, and 3) assess immune modulation of muscle CDKN1A as a...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support Phase I clinical testing of a novel therapeutic agent, termed MN-Anti-miR10B or TTX-MC138, developed by Transcode Therapeutics, Inc. The therapy aims to selectively target and eradicate metastatic tumor cells by inhibiting miRNA-10B, a validated driver of metastasis. Preclinical studies have shown the therapy can mediate regression of metastases in animal models with no evidence of...

The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $3,157,784 Project Grant to Synthis Therapeutics, Inc. to conduct in vivo efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) analysis of SYN101, a first-in-class immune cell-targeted TGFβ therapy for cancer patients. The goals of the 22-month project are to: 1) test the efficacy of SYN101 in humanized mouse tumor models and define the comprehensive immune response, and...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...